News headlines about Audentes Therapeutics (NASDAQ:BOLD) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Audentes Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.3061987701688 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $27.47 on Wednesday. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, meeting the consensus estimate of ($0.88). equities analysts forecast that Audentes Therapeutics will post -3.52 EPS for the current fiscal year.
A number of equities analysts have commented on BOLD shares. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. BidaskClub cut Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. ValuEngine cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $29.00 price target (up previously from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Finally, BMO Capital Markets began coverage on Audentes Therapeutics in a report on Tuesday, December 5th. They issued an “outperform” rating and a $35.00 price target for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Audentes Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $28.29.
In related news, CEO Matthew R. Patterson sold 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $25.06, for a total value of $250,600.00. Following the completion of the transaction, the chief executive officer now directly owns 1,542 shares in the company, valued at $38,642.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 761,500 shares of company stock valued at $21,457,100. Insiders own 47.30% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.